1\. Female patients aged 18-70 years. 2. ECOG performance status of 0-2. 3. Newly diagnosed invasive breast cancer, underwent breast-conserving surgery plus axillary lymph node dissection, with positive axillary lymph nodes (ypN+) and negative surgical margins.
4\. No distant metastasis. 5. Capable of tolerating radiotherapy. 6. For ER/PR-positive patients, willing to receive anticipated 5 years of endocrine therapy.
7\. For HER2-positive patients, willing to receive anticipated 1 year of anti-HER2 targeted therapy.
8\. For patients requiring neoadjuvant/adjuvant chemotherapy, must have completed chemotherapy.
9\. Left ventricular ejection fraction (LVEF) measured by echocardiography is 50%.
10\. Must undergo adjuvant IMRT (Intensity-Modulated Radiation Therapy). 11. Capable of tolerating lying still on the treatment accelerator bed for 30 minutes to complete All-In-One radiotherapy.
12\. Have follow-up conditions and are willing to adhere to follow-up. 13. Signed an informed consent form.
You may not be if
1\. Synchronous bilateral breast cancer; sentinel lymph node biopsy of the axilla was performed without axillary lymph node dissection.
2\. Stage I breast reconstruction surgery or expander implantation surgery on the affected side chest wall.
3\. The purpose of radiotherapy is palliative. 4. Myocardial infarction within the last 3 months or uncorrected unstable arrhythmia or uncorrected unstable angina.
5\. History of chest wall or supraclavicular radiotherapy in the past; past or concurrent second primary malignant tumors (except for non-melanoma skin cancer, papillary/follicular thyroid carcinoma, and carcinoma in situ of the cervix).
6\. All-in-one one-stop radiotherapy has not been completed.
Clareo Health | A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
